<DOC>
	<DOCNO>NCT03065023</DOCNO>
	<brief_summary>This Phase I/II multicenter , first-in-human open-label , dose escalation study evaluate safety , tolerability , anti-tumor activity intratumoral/intralesional injection RGT100-PEI subject select advanced recurrent tumor .</brief_summary>
	<brief_title>Phase I/II Trial Intralesional Administration RGT100</brief_title>
	<detailed_description />
	<criteria>1 . Male female age ≥ 18 year 2 . Subjects histologically cytologically confirm diagnosis advance recurrent tumor ( include lymphoma ) standard treatment use feasible RGT100PEI suitable treatment option : 1 . For Group A : cutaneous , subcutaneous ( s.c. ) , lymph node injectable tumor 2 . For Group B : injectable liver tumor liver metastases 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 4 . Life expectancy &gt; 3 month assess Investigator 5 . Adequate organ function : 1 . Bone marrow function : Hemoglobin ≥ 10 g/dL ( pretreatment transfusion allow ) ; lymphocyte count ≥ 0.5 × 109/L ; absolute neutrophil count ≥ 0.5 × 109/L ; platelet count ≥ 75 × 109/L 2 . Hepatic function : AST ALT ≤ 2 × upper limit normal ( ULN ) ( 3 × ULN case liver metastasis ) ; bilirubin ≤ 1.5 × ULN ( 2 × ULN case liver metastasis ) 3 . Renal function : creatinine &lt; 1.5 × ULN and/or creatinine clearance ≥ 50 mL/min ( Cockroft Gault ) 6 . Negative serum pregnancy test within 2 week first dose study drug subject woman childbearing potential . Subjects subject ' partner childbearing potential must agree use birth control consistently correctly study least 6 month last study drug application . 7 . At least 1 measurable lesion per RECIST 1.1 1 separate injectable lesion diameter ≥ 1 cm &lt; 7 cm 8 . Ability provide write informed consent study drugrelated screening procedure perform 1 . Any tumordirected therapy within 4 week study treatment 2 . Treatment investigational drug within 4 week study enrolment 3 . Systemic steroid dose &gt; 10 mg prednisolone , &gt; 2 mg dexamethasone day equivalent , except topical ( inhaled , topical , nasal ) last 28 day ongoing 4 . Subjects rapidly progress disease ( determined Investigator ) 5 . Ongoing immunerelated adverse event ( irAEs ) and/or AEs ≥ grade 2 resolve previous therapy except vitiligo , stable neuropathy grade 2 , hair loss , stable endocrinopathies substitutive hormone therapy 6 . Within 4 week major surgery 7 . Prior splenectomy 8 . Documented history active autoimmune disorder require systemic immunosuppressive therapy 9 . Primary secondary immune deficiency 10 . Active allergy require systemic medication active infection require antiinfectious therapy 11 . Seropositive ( except vaccination ) human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) 12 . Clinically significant cardiac disease include heart failure ( New York Heart Association , Class III IV ) , preexist arrhythmia , uncontrolled angina pectoris , myocardial infarction within 1 year study entry 13 . Dementia alter mental status would prohibit informed consent 14 . Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study assess Investigator 15 . History stroke , seizure , encephalitis , multiple sclerosis 16 . Gastric ulcer inflammatory bowel disease Crohn 's disease ulcerative colitis last 6 month 17 . Active drug alcohol abuse 18 . Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced tumor</keyword>
	<keyword>intratumoral injection</keyword>
	<keyword>intralesional injection</keyword>
</DOC>